Schubert & CO Abb Vie Inc. Transaction History

Schubert & CO

$99.7 Million
Q1 2024

A detailed history of Schubert & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Schubert & CO holds 1,164 shares of ABBV stock, worth $199,649. This represents 0.21% of its overall portfolio holdings.

Number of Shares

1,164

Holding current value

$199,649

% of portfolio

0.21%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$159.82 - $182.1 $186,030 - $211,964	1,164 New	1,164 $211,000
Q2 2023 Aug 04, 2023	SELL	$132.51 - $164.9 $6,360 - $7,915	-48 Reduced 3.07%	1,517 $204,000
Q1 2023 May 02, 2023	SELL	$144.61 - $166.54 $58,856 - $67,781	-407 Reduced 20.64%	1,565 $249,000
Q4 2022 Jan 31, 2023	BUY	$138.31 - $165.87 $11,203 - $13,435	81 Added 4.28%	1,972 $318,000
Q3 2022 Oct 21, 2022	BUY	$134.21 - $153.93 $1,610 - $1,847	12 Added 0.64%	1,891 $254,000

Q2 2022 Aug 01, 2022	BUY	$137.62 - $174.96 $237,669 - $302,155	1,727 Added 1136.18%	1,879 $288,000
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $5,279 - $6,550	40 Added 35.71%	152 $25,000
Q4 2021 Jan 28, 2022	BUY	$107.43 - $135.93 $12,032 - $15,224	112 New	112 $15,000

Others Institutions Holding ABBV

# of Institutions

3,651

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

Vanguard Group Inc Valley Forge, PA

170M
Shares

$29.2 Billion
0.62% of portfolio
Black Rock Inc. New York, NY

143M
Shares

$24.5 Billion
0.61% of portfolio
State Street Corp Boston, MA

78M
Shares

$13.4 Billion
0.64% of portfolio
Jpmorgan Chase & CO New York, NY

51.3M
Shares

$8.79 Billion
0.85% of portfolio
Capital International Investors Los Angeles, CA

48.1M
Shares

$8.25 Billion
1.81% of portfolio

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $303B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

News

Stay updated on Schubert & CO with notifications on news.

Account